Loading... Please wait...
Sort by:


dossier-jpg.jpgDossier
reports present unbiased and concise analysis based on interviews with leading industry experts on important trends and challenging issues affecting the pharma industry today. 

  • The Impact of Nanomedicine in the Pharma Industry
    Learn More The Impact of Nanomedicine in the Pharma Industry
    Can nanomedicines really offer pharma a compelling alternative approach to precision medicines? Delivering accurate diagnosis for clinicians, safer medicines for patients and lower costs through reduced waste and costly...
  • Dark Analytics: Shining a Torch for Pharma
    Learn More Dark Analytics: Shining a Torch for Pharma
    Dark analytics can unlock a wealth of new clinical and commercial insights—but how can you make it work for you? Dark data and dark analytics have the potential to generate huge business insights, but much of this...
  • Paying for Digital Health:  Payer Insights
    Learn More Paying for Digital Health: Payer Insights
    Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...
  • New Commercial Models: Benchmarking Pharma Companies [2018]
    Learn More New Commercial Models: Benchmarking Pharma Companies [2018]
    How well has your business transitioned from a volume-driven to a value-driven model? Pharma has made the shift from volume to value, but just how successful are these new commercial models proving to be? Customer first...
  • Medical Affairs in Emerging Markets
    Learn More Medical Affairs in Emerging Markets
    How can medical affairs capability be enhanced to unlock the Brazilian, Russian, Indian and Chinese pharma markets? The pharma markets of Brazil, Russia, India and China (BRIC) are becoming increasingly complex with...
  • Biosimilars: US Payer Perspectives (2018)
    Learn More Biosimilars: US Payer Perspectives (2018)
    US payers eye European biologics market with envy Biosimilars may be a roaring success in Europe but the picture in the US couldn't be more different. Once hailed as a solution to stem the tide of soaring drug spending,...
  • Benchmarking Pharma’s MSL Capabilities
    Learn More Benchmarking Pharma’s MSL Capabilities
    Are you convinced your MSL teams are keeping up with evolving market practice? The best medical science liaison (MSL) teams have made significant changes to adapt to a whole new world. The pharma companies getting the...
  • Benchmarking Key Account Management Capabilities
    Learn More Benchmarking Key Account Management Capabilities
    Are your KAM teams firing on all cylinders? If, not, why not? What makes a great KAM (Key Account Manager) and KAM team and what are the personal attributes and operational environment that will deliver optimum...
  • KAM Metrics: Driving efficiency and measuring success
    Learn More KAM Metrics: Driving efficiency and measuring success
    Sales numbers are no longer the gold standard for measuring commercial success. What is? The maturing key account management (KAM) model has transformed the way customer-facing teams operate: the challenge now is to use...
  • Biosimilars: EU Payer Perspectives
    Learn More Biosimilars: EU Payer Perspectives
    Leading European payer experts reveal the real impact of biosimilars over the last 12 months Keeping track of the dynamics and nuances of the biosimilars market is critical – not least because the $232 billion...
  • MSL Teams: Field Force size and structure
    Learn More MSL Teams: Field Force size and structure
    Medical Science Liaison (MSL) personnel play an ever crucial and widening role in communicating the value and science of increasingly complex therapies to opinion leaders and stakeholder groups. The challenge for senior...
  • Pricing and Reimbursement in Neurology
    Learn More Pricing and Reimbursement in Neurology
    When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...
  • Charting the Global Biosimilar Pipeline
    Learn More Charting the Global Biosimilar Pipeline
    There are multiple biosimilars in development for a range of therapy areas from cancer and diabetes to ophthalmology and respiratory. High-value mAbs such as Roche's Avastin (bevacizumab), Abbvie's Humira (adalimumab)...
  • Pricing and Reimbursement in Oncology: Payer views
    Learn More Pricing and Reimbursement in Oncology: Payer views
    As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable...
  • Ambitions in Health: Tech companies step up the pace
    Learn More Ambitions in Health: Tech companies step up the pace
    As investment $$$ pour into digital health projects, the scope and scale of tech giants' ambitions in health become ever clearer. From drug discovery and clinical research to patient monitoring and disease management,...
  • Value-Added Services in Oncology: What motivates payers?
    Learn More Value-Added Services in Oncology: What motivates payers?
    Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence,...
  • The ROI of Orphan Drugs: Ensuring Optimal Returns
    Learn More The ROI of Orphan Drugs: Ensuring Optimal Returns
    Orphan drugs are at the forefront of medical science and offer a chance for the pharma industry to make a real difference to people's lives; there's also the lure of potentially lucrative commercial benefits for those...
  • Orphan Drug Launch Strategies: Case Studies
    Learn More Orphan Drug Launch Strategies: Case Studies
    Achieving commercial success for orphan drugs requires specific strategies to be adopted, not least because market barriers are very different from those encountered when launching more common disease therapies. Lack of...
  • The Importance of Real World Evidence in Orphan Drugs
    Learn More The Importance of Real World Evidence in Orphan Drugs
    Proof of value is an imperative for orphan drug manufacturers: it's the only route to improving patient access and overcoming unmet therapeutic needs for rare conditions. Progress has been made with real world data (RWD)...
  • Market Access Team Structure and Function: Industry Survey 2017
    Learn More Market Access Team Structure and Function: Industry Survey 2017
    This report gives a unique insight into how US and European market access teams are organized and how they are focusing their time on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved